-

Eurofins Forensics Adds Significant COVID-19 Testing Capacity to the UK With Home Testing Roll-Out

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific, a global scientific testing Group has brought together its UK laboratories across multiple disciplines to work together to facilitate increased direct to consumer COVID-19 testing, significantly increasing the UK’s current testing capacity.

The combined resources of Eurofins Forensics, Eurofins Clinical Diagnostics and Eurofins Food & Water Testing will facilitate up to 350,000 tests per week, made available to the general public via home test kits.

The move will see nearly 300 employees working 24/7 to process the samples at five laboratory sites, some of the largest and busiest clinical diagnostics and scientific testing centres in the country. Results are provided electronically, and can also be delivered alongside a travel certificate, for those needing to make essential international journeys.

The home test kits can be delivered to hotels, self-isolation locations and quarantine addresses. A result is returned within 12 to 24 hours and can be used in support of the international traveller’s requirements in each of the nations in the UK. Eurofins is on the Government’s approved list of COVID-19 testing service providers.

The UK testing rollout follows significant capex and R&D investments by parent company Eurofins Scientific, a global leader in bio-analysis. Eurofins has built capacity to facilitate 20 million COVID-19 patient tests per month globally. The Group has established widespread PCR testing capabilities and has carried out well over 10 million PCR tests to date in its own laboratories. It is using its in-house developed NovaPrime testing kits, which are also being supplied to other specialist PCR testing laboratories globally, as well as NGS and PCR tests for rapid identification of new variants of concern.

More information can be found at www.eurofins.co.uk/pcr-testing-kits

Notes to Editors

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

Contacts

For further information:
Investor Relations
ir@eurofins.com

Simon Ward
SimonWard@eurofins.co.uk

Eurofins Scientific

BOURSE:ERF

Release Versions

Contacts

For further information:
Investor Relations
ir@eurofins.com

Simon Ward
SimonWard@eurofins.co.uk

More News From Eurofins Scientific

Eurofins Scientific SE: Weekly Report on Share Repurchases from 23rd April to 24th April 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 23/04/2026 FR0014000MR3 40 000 61.8744 XPAR EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 23/04/2026 FR0014000MR3 10 000 61.9124 CEUX EUROFINS SCIENTIFC 529900JEHFM47D...

Eurofins Launches Seventh Buy-Back Programme of Its Own Shares

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (the “Company”) (EUFI.PA) (Paris:ERF) announces its intention to launch a new buy-back programme of its own shares (ISIN FR0014000MR3) for a maximum amount representing up to 4.5% of its share capital. The maximum amount meant for the repurchase of the Company’s shares may not exceed a sum corresponding to an amount equivalent to the value of 4.5% of the shares composing the share capital of the Company as of the Board of Dire...

Eurofins Achieves Organic Growth of 2.6% in Q1 2026, Including Impact of Exceptionally Severe Weather; 2026 and Mid-Term Objectives Reiterated

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: The Eurofins (Paris:ERF) network of companies delivered steady growth despite significant temporary headwinds: Reported revenues in Q1 2026 totalled €1,789m, an increase of 1.3% vs Q1 2025. This was driven by both organic growth13 and acquisitions, with a -4.8% headwind from foreign exchange as the Euro strengthened against most currencies compared to the prior year quarter. Organic revenue growth13 in Q1 2026 was 2.6%, which includes a +0.1% adjust...
Back to Newsroom